Abstract
replacing the BNT with an alternative measure, as in NACC) poses difficulties when comparing results across studies or within a longitudinal study that has transitioned between versions.
In order to gauge the feasibility of aggregating data from alternate BNT forms over time, we examined performance characteristics of the BNT with the data from participants enrolled in the UK-ADC longitudinal cohort. The UK-ADC adopted the 60-item BNT in 2005, after the CERAD BNT-15 had been administered previously from 1989 to 2005 [16] . To determine the ability of each BNT short form to discriminate between cognitively normal and impaired participants, the diagnostic accuracy of each 15-item and 30-item form was examined in groups of individuals classified as having normal cognitive functioning, mild cognitive impairment (MCI), or dementia. For the purposes of replicating previous analyses within a large and longitudinally followed sample, the current analysis also includes correlations between each short form and the full 60-item BNT. Internal consistencies of each short form are also reported.
Methods

Participants
The participants were research volunteers in the UK-ADC longitudinal cohort, a study of older adults established in 1985 [16, 22] . The University of Kentucky's Institutional Review Board approved all research activities. The cohort used in this report included 681 people aged ≥ 60 years who had been enrolled in the UK-ADC cohort between 1989 and 2010 and had been administered the full 60-item BNT at least once. Since the 60-item BNT has not been implemented until 2005, those enrolled prior to 2005 do not have data from the 60-item BNT at their baseline assessment. Accordingly, baseline data for our analytical purposes were defined as the first available administration of the 60-item BNT. Of the 681 participants with 60-item BNT data, 270 completed the 60-item BNT at their first visit. The analytical baseline data of the remaining 411 participants were collected on follow-up visits.
Clinical Cognitive Diagnosis
Diagnosis was determined by a clinical consensus involving a team of neurologists and neuropsychologists in accordance with the NACC UDS protocol (Form D1: Clinical Diagnosis -Cognitive Status and Dementia) [23] .
Boston Naming Test
The BNT was administered following the instructions provided as part of a standard neuropsychological battery of tests [14] . All subjects began with item 1 and proceeded until item 60 in ascending order. Each item was scored '1' if correctly answered within 20 s with or without a stimulus cue and '0' otherwise. The test was discontinued if 6 consecutive items were named incorrectly, regardless of whether or not stimulus cues were given.
Items included in each BNT short version are listed in Appendix 1. Mack et al. [10] created four 15-item short versions by assigning the 60 items to 4 sets based on order (Mack15.1-15.4). The 4 Mack 15-item versions were also combined into two 30-item versions: Mack 30A (Mack15.1 plus Mack15.2) and Mack 30B (Mack15.3 plus Mack15.4) [24] . Williams et al. [11] selected those 30 items (Williams30) demonstrating the largest mean differences between AD patients and normal controls. Lansing et al. [9] used a stepwise discriminant analysis to empirically derive a new gender-neutral 15-item short form (Lansing15) with maximum discriminability between 325 AD patients and 719 normal controls. Saxton et al. [12] developed two 30-item short forms of equivalent difficulty by dividing the 60 items based on the performance of community-dwelling adults aged ≥ 65 (Saxton30.A and Saxton30.B). In addition to these versions, we evaluated Odd30 (currently used in NACC), Even30, and the CERAD BNT-15. Each shortened version was constructed from the full 60-item BNT.
Results
The characteristics of the 681 individuals during their first administration of the 60-item BNT are shown in table 1 . Of the 681 individuals, 432 (63.4%) were women; 632 (92.8%) were white. At the time of their first 60-item BNT assessment, the participants' mean age was 75.9 years (range 60-97). The participants had a mean 15.8 years of education (range 5-28). 506 (74.3%) were diagnosed as cognitively normal, 105 (15.4%) with MCI, and 70 (10.3%) with dementia. Figure 1 shows the boxplots of the short versions within each diagnostic category. To compare between the full and short versions, the total score of the 60-item BNT was divided by 4 for the 15-item short versions and by 2 for the 30-item short versions. Except for the CERAD BNT-15, the patterns of the various 15-item scores reflect that of the 60-item BNT. The mean of the CERAD BNT-15 was significantly higher than that of other 15- Meanwhile, the patterns of the 30-item score means reflected that of the 60-item BNT score except for Williams30. The mean of Williams30 was more likely to be lower than that of other 30-item versions in those with cognitive impairment (Appendix 2). Again, other than the CERAD BNT-15 (r = 0.689), Spearman's correlation coefficients between each of the short versions and the 60-item BNT were high in all diagnostic groups, ranging from 0.823 to 0.971. The correlations between the CERAD BNT-15 and the 60-item BNT were significantly lower than those of other short versions (p = 0.004) even by type of diagnosis ( table 2 ) . The 60-item BNT had a high Cronbach's α coefficient when all data were Tables 3 and 4 show the AUCs for each BNT version based on BNT alone (unadjusted) and with adjustment for age, gender, years of education, and race, respectively. Compared with other versions, the CERAD BNT-15 demonstrated a poorer ability to discriminate between cognitively normal participants and participants with MCI and dementia, with unadjusted AUCs of 0.580 [95% confidence interval (CI) 0.526-0.634] and 0.852 (95% CI 0.798-0.906), respectively. These AUCs improved when logistic regression models were adjusted for age, gender, years of education, and race; however, the CERAD BNT-15 still had lower AUCs than the other versions. While not statistically significantly different from the other high-performing short forms, the Mack15.4 had the greatest nominal ability to discriminate between cognitively normal participants and those with MCI, with an unadjusted AUC of 0.703 (95% CI 0.645-0.761) and adjusted AUC of 0.782 (95% CI 0.733-0.831). Similarly, the Even30 had the best ability to discriminate participants with dementia from participants with normal cognitive function, with an unadjusted AUC of 0.930 (95% CI 0.899-0.961) and an adjusted AUC of 0.940 (95% CI 0.911-0.969).
Discussion
The BNT has multiple forms, each with its own properties regarding the actual construct that is being measured and the ability to aid in discriminating cognitive functioning. The current study evaluated the internal consistency and correlations between six 15-item short versions, seven 30-item short versions, and the full 60-item version of the BNT in participants from the UK-ADC longitudinal cohort. The diagnostic accuracy of each of the short forms was also evaluated across 3 clinical cognitive diagnoses. Four key findings arose from the analyses, which underscore the importance of measure selection. First, the CERAD BNT-15 was likely to generate a higher absolute score than the other 15-item versions within each type of cognitive diagnosis, while Williams30 was likely to generate a lower score than the other 30-item versions, as previously described [9] . Our results are also consistent with Lansing et al. [9] in that both studies found that normal controls and demented patients scored significantly higher in the CERAD BNT-15 than in the 4 Mack15-item versions and the Lansing 15-item version. The CERAD BNT-15 is composed of 10 items of the first half and only 5 of the second half of the 60 BNT items, which generally increase in difficulty. This is an important point that likely explains the inability of the CERAD BNT-15 to discriminate between cognitively normal persons and those with MCI [27] as well as its poor performance relative to the other short forms. If the majority of the test items are easy, persons with very mild impairment are not likely to miss them. Items of greater difficulty pose a more significant challenge that is necessary to make finer discriminations between cognitively normal persons and those with MCI or early AD. It is also important to note that if the CERAD BNT-15 is used clinically to aid in staging AD severity, patients' semantic ability will likely be overestimated. Second, except for the CERAD BNT-15, high correlations were found between the results of the full 60-item BNT and all short versions. Mack15.4, among the 15-item short versions, and Williams30, among the 30-item versions, showed relatively high correlations with the full version and demonstrated consistency across the types of clinical diagnosis. In contrast, the CERAD BNT-15 had a poor correlation with the 60-item BNT (below 0.7) in cognitively normal subjects. Although correlations between the CERAD BNT-15 and the 60-item BNT were acceptable in the MCI (r = 0.73) and dementia (r = 0.87) groups, the CERAD BNT-15 still displayed the lowest correlation with the 60-item BNT among all of the short forms. Again, the fact that the item structure for the CERAD 15-item version does not appear comparable to the other short forms may have played a role in this finding.
Third, as expected, the full 60-item BNT had the highest Cronbach's α (internal consistency) because it is sensitive to the number of items. Even with this consideration, the CERAD BNT-15 showed markedly low internal consistency in the normal group (α = 0.386), while all other short forms were at or above 0.507. Williams30 had a good internal consistency across the diagnoses compared with the other 30-item versions. All short forms were reliable within the MCI and dementia groups.
Lastly, according to the investigation of the AUCs, the CERAD BNT-15 had a poor diagnostic accuracy between cognitively normal participants and participants with MCI compared with the other versions. Although the accuracy improved when adjusted for age, gender, years of education, and race (26.4% improvement for MCI), the diagnostic accuracy (normal vs. MCI) among all short forms was poor. Nevertheless, the CERAD BNT-15 discriminated between cognitively normal participants and participants with dementia approximately as well as the other short versions. Our results are generally consistent with other findings in this regard. Given that the CERAD BNT-15 is composed of a much easier item set, most participants without advanced cognitive impairment (i.e., cognitively normal and MCI) will not miss many items. Cognitive decline to dementia is a process that occurs over many years, and subtle cognitive impairments will only be revealed when a person's limits are sufficiently tested with more challenging items.
Also of note, the AUC of the 60-item BNT was only 0.694 (without covariate adjustment) when discriminating between cognitively normal participants and those with MCI; when covariate adjustment was added, it improved to 0.776. This is not surprising given that MCI presents in a variety of different ways, not all of which include deficits in confrontation naming. For future research endeavors, it will be important to recognize the variability in MCI cognitive presentations and underlying etiologies. Ideally, persons with MCI would not be aggregated into one group but would be separated by the type of MCI [28] [29] [30] [31] or suspected etiology. Here, we aggregated 8 nonamnestic and 97 amnestic MCI subjects due to the relatively low number of nonamnestic individuals. When examining each MCI subset separately (data not shown), discriminating between nonamnestic MCI and cognitively normal subjects was more difficult, and the estimated confidence intervals for the corresponding AUCs were approximately 3 times the width. Results using only amnestic MCI participants were similar to those with aggregated MCI subjects.
All short BNT versions were able to discriminate well between cognitively normal participants and those with dementia, with covariate adjustments improving the discrimination ability. The short forms performed well compared to the full 60-item BNT for discriminating between cognitively normal participants and those with MCI; however, the capacity for discriminating MCI against normal cognition was noticeably weaker. For the purposes of clinical use, Mack15.4 performed well relative to the other forms while taking into account ease of administration. In particular, Mack15.4 obtained the highest AUC for discriminating between normal and MCI subjects in both unadjusted and adjusted analyses, outperforming even the full 60-item BNT. It also performed well regarding discrimination between normal and dementia diagnoses and had the greatest separation between amnestic and nonamnestic MCI means (data not shown) among the 15-item tests. It must be reiterated, however, that confidence intervals for AUC overlap considerably between these short forms so that care must be taken when assessing best performance.
The full 60-item BNT used in the UK-ADC permitted the exploration of comparison between multiple BNT short-form versions and revealed the pitfalls of switching measures during the course of a study, namely that data arising from such protocols must be handled with care and should not be assumed to be equivalent. Tasks involving discrimination between cognitively normal and demented individuals will be well suited for the adoption of a harmonized BNT score, e.g., simply scaling to the same maximum scores across studies. Other neuropsychological measures that have varied by cohort as well as within a cohort can be ap proached in a similar manner to discern the ability to develop measures that can be appropriately incorporated in meta-analytic frameworks.
This study has some limitations. A number of the participants, including those with MCI and dementia, had been exposed to the CERAD BNT-15 prior to their first administration of the 60-item BNT. It is possible that practice effects elevated the scores on the BNT with repeated longitudinal assessment [27, 32, 33] . All short-form scores were derived via the full version. This may not correspond to the actual score if only a short form was administered. Additionally, the level of education in this sample was high (average of 15.8 years). The BNT is affected by the educational level [34] ; thus, our findings may be different in a less educated sample. Similarly, interstudy differences in other potential confounders (e.g., ethnicity) may limit generalizability. Finally, because the BNT is used in the clinical consensus process per NACC UDS protocol, there may be some conflation regarding the independent predictive ability for cognitive diagnosis.
In summary, these results have important implications for the ability to use a uniform measure for the BNT when examining risk factors and covariates for dysnomia across multiple cohorts. Aside from the CERAD BNT-15, the internal consistency and high correlation between the short forms and the full BNT allow the adoption of a uniform measure across disparate data sources without much loss of information. This can be achieved relatively easily, by, for example, assimilation to a common range across all BNT forms. 
